EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Daisuke Sakai iD, Shigenori Kadowaki iD, Ryohei Kawabata, Hiroki Hara iD, Hironaga Satake iD, Masazumi Takahashi iD, Atsushi Takeno, Hiroo Imai, Keiko Minashi iD, Takeshi Kawakami iD, Shogen Boku iD, Jin Matsuyama und 7 weitere

Journal of Clinical Oncology · 2025-07 · 43 (19) · 2196-2207

DOI: 10.1200/jco.24.01119 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-07. Verfasst von Daisuke Sakai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Irinotecan, Stomach Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Continuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. This trial aimed to compare the efficacy and safety of ramucirumab plus irinotecan with irinotecan monotherapy as a third- or later-line treatment for patients with advanced or recurrent gastric or gastroesophageal cancer (AGC) that has progressed on previous ramucirumab-based chemotherapy. METHODS Patients age 20 years and older with AGC, who had experienced disease progression during ramucirumab-based chemotherapy, were randomly assigned to receive either ramucirumab plus irinotecan or irinotecan monotherapy. The primary end point was overall survival (OS) expecting a hazard ratio (HR) of 0.77 (a power of 80% and a significance level of one-sided 0.05). Secondary end points included progression-free survival (PFS), response rate, disease control rate (DCR), and safety. RESULTS Between February 2017 and August 2022, 402 patients in Japan were randomly assigned to receive ramucirumab plus irinotecan (n = 202) or irinotecan monotherapy (n = 200). The median OS was 9.4 months in the combination arm and 8.5 months in the monotherapy arm, with an adjusted HR of 0.91 (95% CI, 0.74 to 1.12; P = .49). PFS was improved (median, 3.8 v 2.8 months; HR, 0.72 [95% CI, 0.59 to 0.89]; P = .002), while the DCR was significantly better (64.4% v 52.1%; P = .03) with the combination therapy. The adverse events of the combination therapy were manageable. CONCLUSION Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsIrinotecanStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease ProgressionDrug Resistance, NeoplasmProgression-Free SurvivalRamucirumab

Substanzen

Antibodies, Monoclonal, HumanizedIrinotecanRamucirumab

Autor:innen und Institutionen

  • Osaka International Cancer Institute, Osaka, Japan.
  • Osaka University Hospital, Suita, Japan.
  • Aichi Cancer Center Hospital, Nagoya, Japan.
  • Osaka Rosai Hospital, Sakai, Japan.
  • Saitama Cancer Center, Ina, Japan.
  • Kobe City Medical Center General Hospital, Kobe, Japan.

ORCID-Profile: Daisuke Sakai, Shigenori Kadowaki, Hiroki Hara, Hironaga Satake, Masazumi Takahashi, Keiko Minashi, Takeshi Kawakami, Shogen Boku, Kentaro Sawada, Hisato Kawakami, Narikazu Boku, Taroh Satoh

Zitieren

APA

Sakai, D., Kadowaki, S., Kawabata, R., Hara, H., Satake, H., Takahashi, M., Takeno, A., Imai, H., Minashi, K., Kawakami, T., Boku, S., Matsuyama, J., Sakamoto, Y., Sawada, K., Kataoka, M., Kawakami, H., Shimokawa, T., Boku, N., & Satoh, T. (2025). Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Journal of Clinical Oncology, 43(19), 2196-2207. https://doi.org/10.1200/jco.24.01119

Vancouver

Sakai D, Kadowaki S, Kawabata R, Hara H, Satake H, Takahashi M, et al. Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Journal of Clinical Oncology. 2025;43(19):2196-2207. doi:10.1200/jco.24.01119

BibTeX
@article{Sakai2025,
  author = {Sakai, Daisuke and Kadowaki, Shigenori and Kawabata, Ryohei and Hara, Hiroki and Satake, Hironaga and Takahashi, Masazumi and Takeno, Atsushi and Imai, Hiroo and Minashi, Keiko and Kawakami, Takeshi and Boku, Shogen and Matsuyama, Jin and Sakamoto, Yasuhiro and Sawada, Kentaro and Kataoka, Masato and Kawakami, Hisato and Shimokawa, Toshio and Boku, Narikazu and Satoh, Taroh},
  title = {Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {19},
  pages = {2196--2207},
  doi = {10.1200/jco.24.01119}
}
Kostenlos starten →